Briefs

Does CYP2D6 Predict Who Benefits From Tamoxifen?

BY MELISSA WEBER

A new study that found "slow metabolizers" of tamoxifen did not have a higher risk of recurrence has spurred further controversy over whether patients who don't fully metabolize the drug get the full benefit... [MORE]

Nexavar Slows the Progression of Breast Cancer

BY MELISSA WEBER

A drug that treats liver and kidney cancer delayed locally recurrent or metastatic HER2-negative breast cancer in two phase 2 studies presented Friday at the San Antonio Breast Cancer Symposium. Nexavar (sorafenib)... [MORE]

Why Prophylactic Mastectomy Rates Are Increasing

BY LAURA BEIL

Consistent with previous research, data presented Friday has found that a woman diagnosed with breast cancer is more likely to undergo mastectomy of the healthy breast, called prophylactic mastectomy, if she has an... [MORE]

Blogs

DEBU TRIPATHY, MD

The Importance of Cellular Pathways and Updates on Anti-angiogenic Drugs

Today's morning session started off with a heavy dose of basic science—two important pathways were discussed. One is a... [MORE]

KATHY LATOUR

Prophylactic Mastectomy on Other Breast Increasing

It wasn't surprising to me today to hear data that showed a large increase in women choosing prophylactic mastectomy on the side not affected by breast... [MORE]

SUSAN MCCLURE

New Mammography Guidelines Continue to Spark Debate

You'll recall the public outcry that occurred in October when the U.S. Preventive Services Task Force issued a report... [MORE]

BEV PARKER

Trial Tests New Drugs, Male Breast Cancer Detailed

Breast cancer advocates at the San Antonio Breast Cancer Symposium have many opportunities to be involved and to learn. Two of my favorites today were the I-SPY... [MORE]

Message Board

Did your doctor prescribe Avastin to treat your breast cancer? Share your experience with the drug on the CURE Message Board.

PROFILE:

Two Komen Advocates Focus on the Local and the Global

BY KATHY LATOUR

Chris Tannous, PhD, and Dorothy Paterson have given their lives to advocacy in two very different ways... [MORE]

Become a fan of CURE on Facebook.

Follow CURE on Twitter.

Send feedback to editor@curetoday.com.

Sign up for our e-mail newsletters, which you can now personalize by tumor type, survivorship, or caregiver status.

This e-mail was sent to you because you have provided your e-mail address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

Please add enews@curetoday.com to your address book or safe sender list to ensure this e-mail is delivered to your inbox.

2009 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic, or treatment advice.